LRMR
LRMR
NASDAQ · Biotechnology

Larimar Therapeutics Inc

$3.37
+0.30 (+9.77%)
As of Feb 8, 1:59 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 175.11M 171.92M 184.32M
Net Income -19,494,630 -18,016,562 -21,970,966
EPS
Profit Margin -11.1% -10.5% -11.9%
Rev Growth -5.1% +17.2% +14.9%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 116.92M 97.87M 111.57M
Total Equity 169.45M 168.38M 165.86M
D/E Ratio 0.69 0.58 0.67
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -28,814,403 -28,168,357 -29,490,113
Free Cash Flow -20,989,250 -18,411,143 -19,560,158